ERBB2 and breast cancer: The NeoSphere study found that in patients with HER-2-positive breast cancer, preoperative neoadjuvant chemotherapy (NAC) combined with dual anti-HER-2 therapy (trastuzumab and pertuzumab) significantly increased pathologic complete response (pCR) compared with chemotherapy combined with single anti-HER-2 therapy.